85 related articles for article (PubMed ID: 28830934)
1. OP449 inhibits breast cancer growth without adverse metabolic effects.
Shlomai G; Zelenko Z; Antoniou IM; Stasinopoulos M; Tobin-Hess A; Vitek MP; LeRoith D; Gallagher EJ
Endocr Relat Cancer; 2017 Oct; 24(10):519-529. PubMed ID: 28830934
[TBL] [Abstract][Full Text] [Related]
2. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
[TBL] [Abstract][Full Text] [Related]
3. PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
Galiger C; Dahlhaus M; Vitek MP; Debatin KM; Beltinger C
Front Oncol; 2022; 12():744984. PubMed ID: 35814385
[TBL] [Abstract][Full Text] [Related]
4. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
6. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
De Angel RE; Conti CJ; Wheatley KE; Brenner AJ; Otto G; Degraffenried LA; Hursting SD
Mol Carcinog; 2013 Jun; 52(6):446-58. PubMed ID: 22290600
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
9. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts.
Venkateswaran V; Haddad AQ; Fleshner NE; Fan R; Sugar LM; Nam R; Klotz LH; Pollak M
J Natl Cancer Inst; 2007 Dec; 99(23):1793-800. PubMed ID: 18042933
[TBL] [Abstract][Full Text] [Related]
10. Renal activity of Akt kinase in obese Zucker rats.
Zdychová J; Kazdová L; Pelikanová T; Lindsley JN; Anderson S; Komers R
Exp Biol Med (Maywood); 2008 Oct; 233(10):1231-41. PubMed ID: 18641049
[TBL] [Abstract][Full Text] [Related]
11. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
12. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
13. Insulinemia and the risk of breast cancer and its relapse.
Formica V; Tesauro M; Cardillo C; Roselli M
Diabetes Obes Metab; 2012 Dec; 14(12):1073-80. PubMed ID: 22537210
[TBL] [Abstract][Full Text] [Related]
14. Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts.
Bertacca A; Ciccarone A; Cecchetti P; Vianello B; Laurenza I; Maffei M; Chiellini C; Del Prato S; Benzi L
Metabolism; 2005 Dec; 54(12):1687-93. PubMed ID: 16311104
[TBL] [Abstract][Full Text] [Related]
15. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
16. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
[TBL] [Abstract][Full Text] [Related]
17. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.
Matà R; Palladino C; Nicolosi ML; Lo Presti AR; Malaguarnera R; Ragusa M; Sciortino D; Morrione A; Maggiolini M; Vella V; Belfiore A
Oncotarget; 2016 Feb; 7(7):7683-700. PubMed ID: 26655502
[TBL] [Abstract][Full Text] [Related]
18. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
[No Abstract] [Full Text] [Related]
[Next] [New Search]
